Opaleye Management as of Dec. 31, 2018
Portfolio Holdings for Opaleye Management
Opaleye Management holds 47 positions in its portfolio as reported in the December 2018 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Codexis (CDXS) | 10.9 | $29M | 1.8M | 16.70 | |
| Axogen (AXGN) | 9.9 | $27M | 1.3M | 20.43 | |
| Loxo Oncology | 9.2 | $25M | 175k | 140.07 | |
| Amarin Corporation | 6.3 | $17M | 1.3M | 13.61 | |
| Blueprint Medicines (BPMC) | 6.0 | $16M | 300k | 53.91 | |
| Imprimis Pharmaceuticals | 3.7 | $9.8M | 1.7M | 5.69 | |
| Fibrogen | 3.5 | $9.3M | 200k | 46.28 | |
| Deciphera Pharmaceuticals | 2.7 | $7.1M | 340k | 20.99 | |
| Epizyme | 2.6 | $6.9M | 1.1M | 6.16 | |
| Ptc Therapeutics I (PTCT) | 2.4 | $6.5M | 190k | 34.32 | |
| Xencor (XNCR) | 2.4 | $6.5M | 180k | 36.16 | |
| Viking Therapeutics (VKTX) | 2.4 | $6.3M | 825k | 7.65 | |
| Strongbridge Bioph shs usd | 2.3 | $6.2M | 1.4M | 4.48 | |
| Cerecor | 2.3 | $6.2M | 2.2M | 2.84 | |
| Sangamo Biosciences (SGMO) | 2.1 | $5.7M | 500k | 11.48 | |
| Fennec Pharmaceuticals (FENC) | 2.1 | $5.7M | 900k | 6.38 | |
| Cymabay Therapeutics | 2.1 | $5.7M | 725k | 7.87 | |
| Polarityte | 2.0 | $5.4M | 400k | 13.49 | |
| Audentes Therapeutics | 2.0 | $5.3M | 250k | 21.32 | |
| Chimerix (CMRX) | 1.9 | $5.2M | 2.0M | 2.57 | |
| Xoma Corp Del (XOMA) | 1.9 | $5.1M | 400k | 12.65 | |
| ImmunoGen | 1.8 | $4.9M | 1.0M | 4.80 | |
| Apellis Pharmaceuticals (APLS) | 1.4 | $3.6M | 275k | 13.19 | |
| Aimmune Therapeutics | 1.3 | $3.6M | 150k | 23.92 | |
| Abeona Therapeutics | 1.2 | $3.2M | 450k | 7.14 | |
| Eton Pharmaceuticals (ETON) | 1.2 | $3.2M | 523k | 6.12 | |
| ACADIA Pharmaceuticals (ACAD) | 1.2 | $3.2M | 195k | 16.17 | |
| Tricida | 1.1 | $2.9M | 123k | 23.58 | |
| Magenta Therapeutics | 1.1 | $2.9M | 505k | 5.70 | |
| Cidara Therapeutics Inc Common Stock Usd 0.0001 | 1.1 | $2.8M | 1.2M | 2.35 | |
| Avenue Therapeutics | 1.0 | $2.7M | 496k | 5.40 | |
| Tg Therapeutics (TGTX) | 0.8 | $2.3M | 550k | 4.10 | |
| Puma Biotechnology (PBYI) | 0.8 | $2.0M | 100k | 20.35 | |
| Eidos Therapeutics | 0.7 | $1.9M | 140k | 13.76 | |
| Macrogenics (MGNX) | 0.7 | $1.9M | 150k | 12.70 | |
| Clementia | 0.7 | $1.8M | 150k | 11.76 | |
| Zymeworks | 0.6 | $1.5M | 105k | 14.68 | |
| Collegium Pharmaceutical Inc Common Stock Usd (COLL) | 0.5 | $1.4M | 80k | 17.16 | |
| Miragen Therapeutics | 0.4 | $1.2M | 385k | 3.03 | |
| Cti Biopharma | 0.4 | $1.0M | 1.4M | 0.73 | |
| Protalix BioTherapeutics | 0.3 | $775k | 2.5M | 0.31 | |
| Odonate Therapeutics Ord | 0.3 | $690k | 49k | 14.08 | |
| Axovant Sciences | 0.2 | $574k | 580k | 0.99 | |
| Dermira | 0.2 | $539k | 75k | 7.19 | |
| Assertio Therapeutics | 0.2 | $433k | 120k | 3.61 | |
| ArQule | 0.1 | $358k | 200k | 1.79 | |
| Biolinerx Ltd-spons | 0.0 | $110k | 250k | 0.44 |
